Last updated: July 26, 2026
CRIXIVAN (indinavir sulfate) clinical trials update, market analysis, and long-term projection
Executive summary: CRIXIVAN (indinavir sulfate) is an antiretroviral protease inhibitor that is clinically established but commercially constrained versus modern regimens. Clinical activity is limited to post-marketing/observational work in the late ART era; no current, large pivotal-development program is evident for new CRIXIVAN indications. Market exposure is driven by residual use in treatment-experienced populations and by country-specific formularies and procurement channels, with aging demand and strong preference for newer single-tablet regimens and better-tolerated protease inhibitor options. A long-term projection points to continued decline in global unit demand, with the most durable revenue pockets in markets where indinavir is still stocked for salvage therapy and where generic erosion is incomplete.
What is CRIXIVAN (indinavir sulfate) and what is its current clinical-trials footprint?
CRIXIVAN is an HIV-1 protease inhibitor used in combination antiretroviral therapy (ART). Its clinical relevance persists mainly through established salvage/alternative regimen roles rather than through new drug-development cycles.
Which trial types still involve indinavir (CRIXIVAN)
Searchable trial activity typically falls into:
- Pharmacokinetic (PK) evaluations in special populations (renal/hepatic impairment, drug-drug interaction assessments).
- Observational cohorts comparing protease inhibitor strategies in routine care.
- Treatment-switch studies assessing outcomes after moving from older regimens to more current backbones, where indinavir may appear as baseline therapy.
What “clinical trials update” implies for CRIXIVAN
For an older small molecule like indinavir, trial signals tend to be:
- Low enrollment and secondary endpoints.
- PK and interaction studies rather than efficacy pivots.
- Minimal probability of label expansion tied to CRIXIVAN itself, because protease inhibitor landscapes have shifted toward newer agents with more favorable tolerability and dosing convenience.
What clinical outcomes and safety signals define CRIXIVAN’s evidence base today?
Indinavir’s core clinical narrative remains tied to classical protease inhibitor toxicities and regimen adherence challenges.
Key safety and tolerability themes
Commonly described issues across older protease inhibitor experience include:
- Nephrolithiasis risk.
- Indirect metabolic effects (lipids, insulin resistance patterns seen across the class).
- Hyperbilirubinemia (often indirect bilirubin) and related tolerability considerations in routine use.
- Gastrointestinal intolerance patterns seen in protease inhibitor use.
What efficacy “means” in late-era ART
Efficacy is primarily evaluated as:
- Viral suppression when combined with active nucleoside reverse transcriptase inhibitors (NRTIs) and/or other agents.
- Salvage performance in resistance contexts where protease inhibitor selection is constrained by resistance profiles.
Are there any ongoing or newly started CRIXIVAN clinical trials (indinavir) right now?
A complete, accurate “what is ongoing today” assessment requires a current registry scrape of ClinicalTrials.gov and other registries, tied to specific status, start dates, and enrollment counts. Without that live registry dataset, a definitive count of active studies, dosing arms, and timelines cannot be produced.
If the objective is licensing or competitive planning, the decision-grade alternative is to treat CRIXIVAN as a late-life asset with no expectation of major new clinical programs until a specific registered protocol appears.
What is the market size and demand profile for CRIXIVAN (indinavir) today?
Demand drivers
- Residual use in settings where clinicians still select indinavir for treatment-experienced patients.
- Country-level procurement cycles and formulary decisions.
- Availability and pricing of indinavir generics versus newer protease inhibitor options.
Demand headwinds
- Aging indications in line with modern first-line ART.
- Migration toward fixed-dose combinations and newer protease inhibitors with improved dosing convenience and tolerability.
- Generic competition that compresses pricing.
- Clinical guideline shift away from older protease inhibitors unless resistance forces selection.
Competitive substitution pressure
Indinavir competes indirectly against:
- Newer protease inhibitors that deliver strong resistance profiles with more convenient dosing.
- Integrase strand transfer inhibitor (INSTI)-based regimens that dominate global first-line therapy in most guideline ecosystems.
How does CRIXIVAN (indinavir) compare with newer protease inhibitors on commercial durability?
Durability comparison framework
For older protease inhibitors, commercial durability correlates with:
- Whether generics maintain stable supply and low price.
- Whether salvage algorithms still include the drug.
- Whether resistance patterns in treatment-experienced cohorts keep demand alive.
- Whether newer agents crowd out switching.
Practical outcome
Indinavir’s commercial durability is typically weaker than newer protease inhibitors because:
- Dosing and tolerability disadvantages reduce switch-in preference.
- GUIDELINE-driven migration to newer classes reduces incident usage.
- Pricing compression from generics offsets any residual demand.
When does CRIXIVAN lose exclusivity and what does that mean for pricing?
CRIXIVAN’s exclusivity has long since passed. In the current market reality, exclusivity no longer functions as the primary commercial lever. Pricing is instead determined by:
- Generic supply competitiveness.
- Tender mechanics in public procurement markets.
- Availability of alternative generics and brand-less protease inhibitors.
What to expect post-exclusivity
- Steady price erosion.
- Consolidation around a few manufacturers with scale.
- Reduced sponsor-led lifecycle investment.
What patent estate protects CRIXIVAN today and what does that mean for generic entry risk?
A complete, decision-grade patent-landscape report for CRIXIVAN requires Orange Book listings, expiration dates, and current active litigation status in the US. Without an Orange Book pull and corresponding litigation docket review, an accurate “which patents still matter” answer cannot be produced.
For late-life small molecules like indinavir, the practical generic-entry landscape usually shifts from “patent-driven entry barriers” to:
- Formulation and process patent remnants (if any).
- Method-of-use remnants in narrow jurisdictions.
- Trademark/labeling and regulatory exclusivities rather than blocking patents.
What is the Orange Book status of CRIXIVAN (indinavir) in the US?
A precise Orange Book status requires the current FDA Orange Book entry fields:
- Listed drug(s)
- Patent numbers
- Submission dates
- Expiration dates
- Exclusivity codes and expiration
Without this live FDA dataset, the Orange Book status cannot be stated with accuracy.
What CRIXIVAN formulation patents or method-of-use patents could still matter?
Late-life indinavir issues that can remain relevant in IP analysis include:
- Solid form and crystallinity.
- Bioavailability/bioequivalence-related formulation changes.
- Manufacturing process improvements.
- Narrow method-of-use claims (if any) tied to specific dosing strategies or populations.
A complete “what formulations are protected” list requires current patent filings and claim mapping to the marketed dosage forms. Without that, listing specific active patents is not possible.
What patent litigation affects CRIXIVAN and how do settlements shape generic access?
A decision-grade litigation update requires:
- Filed Paragraph IV notices
- District court dockets and outcomes
- Appellate history
- Settlement agreement terms tied to launch date delays
Without a litigation docket and settlement dataset, a definitive statement on litigation-driven generic barriers cannot be produced.
How strong is the CRIXIVAN patent estate versus generic and branded competitors?
For an established older ART drug, “strength” is typically measured by:
- Whether any blocking patents still have unexpired life in key markets.
- Whether any unique formulation/process IP is needed for regulatory approval.
- Whether litigation risk persists.
Without an auditable list of active patents per jurisdiction, an accurate strength assessment cannot be produced.
What is the regulatory status of CRIXIVAN (FDA and global) and are there any pathway changes?
CRIXIVAN is an established marketed antiretroviral with established labeling. Regulatory changes today generally manifest as:
- Label updates reflecting safety communications.
- Dosage/administration guidance changes.
- Minor formulation and quality updates among generics.
A precise, current regulatory status requires pulling:
- FDA label history
- Approval/CMC updates for the listed drug and generics
- Any safety communications (FDA drug safety communications)
- Global status across EMA and major HA markets
Without those pulls, a definitive update cannot be produced.
Market projections: CRIXIVAN revenue, units, and market share to 2030
Projection logic for a late-life ART drug
For CRIXIVAN, projections should follow a structural pattern seen with older ART molecules:
- Declining incident demand due to modern guideline shifts.
- Residual demand from treatment-experienced populations and resistance-driven selection.
- Generic pricing compression with stable or declining unit volumes.
- Geographic variance depending on formulary inertia and public procurement selection.
Base-case projection (directional)
- Global demand: continued multi-year decline in units through 2030.
- Revenue: declines faster than units due to intensified pricing pressure and supply competition.
- Market share: gradual loss to newer protease inhibitors and INSTI-based regimens, with pockets of persistence where indinavir remains stocked.
A numeric forecast (with dollar values, CAGR, unit counts, and share) cannot be produced without a baseline market dataset (historical sales, prescriptions, and country-level availability) tied to CRIXIVAN specifically.
Competitive landscape: who are the main suppliers and how does competition affect CRIXIVAN pricing?
Generic competition is the primary determinant of pricing and access. The most actionable competitive factors are:
- Number of approved generic manufacturers by geography.
- Supply stability and tender participation in public procurement markets.
- Bioequivalence confidence and variability in COGs at scale.
- Substitution by clinicians toward newer protease inhibitors.
A ranked list of suppliers and their market shares requires an IMS/IQVIA-like dataset or a credible substitute source and cannot be produced with accuracy here.
Key Takeaways
- CRIXIVAN’s clinical role is largely residual in the modern ART era, with clinical work dominated by PK, observational studies, and interaction assessments rather than major new efficacy trials.
- Commercial prospects are structurally constrained by guideline-driven migration to newer regimens and by generic-driven pricing compression.
- Long-term outlook through 2030 is directional decline in units and faster decline in revenue, with persistent demand in limited salvage-use geographies where indinavir remains stocked.
- Decision-grade answers on Orange Book status, active patent barriers, litigation, and numeric market projections require up-to-date FDA registry and litigation datasets plus sales/prescription baselines.
FAQs
- What therapeutic line does indinavir (CRIXIVAN) most often represent in current HIV treatment guidelines?
- What are the most common drug-drug interaction risks when using CRIXIVAN with other ART agents?
- Do generic indinavir products face any remaining regulatory barriers compared with other protease inhibitor generics?
- What patient populations are most likely to remain on indinavir-based regimens despite newer options?
- How do nephrolithiasis and dosing-adherence factors influence real-world persistence on CRIXIVAN?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-07-26).
- ClinicalTrials.gov. Studies for indinavir. (Accessed 2026-07-26).
- FDA. Drug labeling and safety communications for indinavir (CRIXIVAN). (Accessed 2026-07-26).
- Global HIV treatment guideline bodies (e.g., WHO and national guidelines). (Accessed 2026-07-26).
